VivoSim Labs (LTS:0R02) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R02 VivoSim Labs Inc LTS:0R02
33 GF Score
Price $3.17
GF Value $11.18
! 6 Warning Signs
View Full Analysis

What is VivoSim Labs Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0R02
33GF Score
VivoSim Labs Inc LTS:0R02
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is VivoSim Labs (LTS:0R02) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of $3.17 is trading 71.6% below its estimated GF Value™ of $11.18.

Key valuation signals for LTS:0R02:

  • Dividends Received:
  • GF Value™: $11.18 vs. price of $3.17 (71.6% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the LTS:0R02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score

Get the complete analysis for LTS:0R02

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.17
Price
$11.18
GF Value